NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Organogenesis Holdings Inc. ORGO
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$564.2M
▲ 17.0% vs FY2024
EPS · FY25
$0.15
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
13.2%
Net margin · FY25
6.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 564.2M
Revenue, FY2025 · full 10-year series below
Revenue
Net income
7 cents of every revenue dollar became profit this year.
Per share
USD 0.15
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
13.2%
Return on equity, FY2025
ROE
Operating margin7.9%
Net margin6.6%
Return on assets6.8%
Each USD of equity produced 13 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+10.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+7.8%
+10.8%
Net income
+33.6%
+16.5%
EPS, diluted
+7.7%
+0.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.13B
Shares outstanding, FY2025
Change, 5 years−0.6%
Change, 10 years—
The share count shrank 1% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 598.7M
total assets, end of FY2025
Total assetsUSD 598.7M
EquityUSD 300.1M
CashUSD 93.7M
Current ratio3.62×
Equity funds 50% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.6
0.5
0.4
0.5
0.5
0.3
0.3
0.2
0.2
0.1
Operating income $B
0.0
−0.0
0.0
0.0
0.1
0.0
−0.0
−0.1
−0.0
−0.0
EBITDA $B
0.1
0.0
0.0
0.0
0.1
0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
Net income $B
0.0
0.0
0.0
0.0
0.1
0.0
−0.0
−0.1
−0.0
−0.0
EPS, diluted $
0.15
0.01
0.04
0.12
0.70
0.15
−0.42
−0.94
−0.14
−0.27
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
13.2
0.3
1.8
6.1
49.2
17.8
−84.2
−526.6
·
·
Shares out B
0.13
0.13
0.13
0.13
0.13
0.00
0.10
0.09
0.07
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
39 of 39
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed